A carregar...
Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
Ovarian cancer is the most lethal gynecologic malignancy. About 75% of ovarian cancer patients relapse and/or develop chemo‐resistant disease after initial response to standard‐of‐care treatment with platinum‐based therapies. HER2 amplifications and overexpression in ovarian cancer are reported to v...
Na minha lista:
| Publicado no: | Mol Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6360362/ https://ncbi.nlm.nih.gov/pubmed/30499260 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12414 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|